Further evidence of the wake-promoting properties of VSF-173 was also observed during the scheduled daytime recovery sleep following the night time and morning evaluations. Statistically significant (p<.05; non-parametric) dose-dependent correlations were observed with the following polysomnography (PSG) parameters: increased number of awakenings, decreased sleep efficiency and total sleep time for the first third of the sleep period, and increased wake time after sleep onset for the first 3 hours of the sleep period.
These wake-promoting effects of VSF-173 on MWT and PSG measures suggest that VSF-173 possesses a novel mechanism to address disorders of excessive sleepiness. Vanda plans to conduct additional studies to further understand timing of administration, dose-response and appropriate populations to treat. VSF-173 was also demonstrated to be safe and well-tolerated.
"We are encouraged by the results of this proof-of-concept study on VSF-173," stated Mihael Polymeropoulos, M.D., President and CEO of Vanda. "We believe that the compound has the potential to address the symptoms of excessive sleepiness in the context of a number of disorders including narcolepsy and shift worker sleep disorder, as well as neurodegenerative disorders."
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company with a
particular focus on the development and commercialization of clinical-stage
product candidates for central nervous system disorders. The company has
three product candidates in clinical development. In addition to VSF-173,
Vanda is developing Iloperidone, a drug for schizophrenia, which has
recently been submitted for marketing approval to the FDA, and VEC-162, a
compound for the treatment of sleep and mood disorders, which h
|SOURCE Vanda Pharmaceuticals Inc.|
Copyright©2007 PR Newswire.
All rights reserved